¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º y?[ v=j*U  
Sz%t JD..  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ mC4zactv  
9A/\h3HrJ  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) `> 7; !  
iQ tN Aj  
1. ICAM-1 j-4VB_N@  
T}Km?d  
2. interleukin 12(IL-12) _D+}q_  
%7"q"A r[  
3. tumor infiltrating lymphocyte 8|):`u  
w,.+IV$Kk  
4. TCR/CD3 complex Sc>,lIM  
q 0$,*[PH  
5. hematopoietin receptor family 9i'jj N  
 J}htu  
6. individual idiotype(IdI) [=" e ziM{  
J4QXz[dG  
7. integrin "oTHq]Ku  
X>d"]GD  
8. colony-stimulatory factor (CSF) !Z`j2 e}  
/,89p&h  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© )jU)_To  
I CZ4 A{I  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? =q>'19^Jx  
JI?rL  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ jq-p;-i  
W 0(_ ~  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷Óᣠ| h`0u'#  
L; T8?+x  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ |S_T^'<W  
/mXBvY  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) @PN#p"KaT  
IM:=@a{  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ P7J>+cm  
{kp-h2I,  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) _.>QEh5"5  
3,>0a  
3. immunoglobulin superfamily (IgSF) * 1T&  
\qR7mI/*  
4. selectin ?f#y1m  
wQv'8A_}  
5. anti-idiotypic antibody (¦ÁId) So{x]x:f  
'HT7_$?*  
6. major histocompatibility complex(MHC) H]Cy=Zi"  
LL]zT H0  
7. immunotolerance 0FGe=$vD  
7bqBk,`9  
8. biological reponse modifier(BRM) MJ7Y#<u  
q:l>O5  
9. immune reponse gene (Ir gene) z|=}1; (.  
=fu :@+  
10. reshaped antibody (or reconstituted antibody) Z= jr-)kK  
^9^WuSq  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© el2bd :  
AP [|Ta  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ 8*8Zc/{  
0.dgoq 3u  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? W)9K`hM6  
]x\-$~E  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ zV:pQRbt.  
cj+ FRG~u  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? %{YN70/  
$tz; <M7B  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ "5;;)\o ~  
M(jgd  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? x\F,SEj  
vN|l\!~  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ " Om[~-31  
/TZOJE(2j  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ S>.SSXlM  
*:>"q ej  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? )jkXS TZ  
m-H-6`]  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ XK|R8rhg8`  
A,\6nO67  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: 8<.C3m 6h  
0j30LXI_  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: N@O8\oQG  
ZKQG:M~|  
ÃâÒßѧ cU{e`<xjA  
.so[I  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© @O@GRq&V  
,$'])A? $  
1. CD8 J9\a{c;.  
.k 3 '  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) vC1v"L;[o/  
,0 E{h}(  
3. immunoglobulin fold(Ig fold) P( XaTU&-  
4hAl-8~Q6  
4. cadherin (Ca-dependent cell adhesion moleculers) p/U+ 0f  
IkrF/$r  
5. idiotype-anti-idiotypic antibody immune network theory :WSDf VX  
3t<a $i  
6. HLA class II antigen zo[[>MA  
1gmt2>#v%  
7. complementarity-determining region (CDR) *^RmjW1I  
"y_#7K  
8. perforin(or pore-forming protein ,PFP) [8Qro8  
' Hi : 2Wh  
9. high affinity IL-2 receptor :$_6SQ<?  
c%[#~;E  
10. artificial active immunization W -  
)ZBY* lk9  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© ++aL4:  
2*N_5&9mE  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠm}8[ #:  
%e`$p=m  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 >[ Ye  
MY/3] g<  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ +=]!P#  
zCOgBT~p   
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ p|Q*5TO  
lj{VL}R  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ <`jLY)sw  
2MATpV#BT  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? {0;3W7  
Dk+&X-]6x5  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ { .*y  
@h*fFiY&{  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ "wlt> SU  
70lfb`  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ fM #7y [  
PG8^.)]M  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ 4*aZ>R2hO  
.<z!3O&L  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© etd&..]J  
`;YU.*  
1. immunoglobulin gene rearrangement gORJWQv  
'kYwz;gp  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors)  49d@!  
2kv7UU#q2  
3. flow cytometry(FCM) vsL[*OeI  
* ,v|y6  
4. carrier effect /t6X(*xoy  
y7S4d~&  
5. positive selection of T lymphocytes in thymus d*oUfiW  
Q#(GI2F2#  
6. mouse TH1(Th1) and TH2(Th2) subsets }|B=h  
__[xD\ES  
7. perforin (pore-forming protein ,PFP) Fkf97O i  
N)S!7%ne  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) <xJ/y|{  
^ FZ^6*  
9. SH-2(src-homology region 2) JbO ~n )%x  
/%A;mlf{  
10. Ab2¦Â (internal image) ubu?S%`  
9s}Kl($  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© KOg?FmD  
\@}#Gez  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? Z?J:$of*  
WZ!WxX>zO  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? F?m?UQS'u  
hh~n#7w~IR  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦Óᣠy<XlRTy[}  
hF3&i=;.  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ }j1!j&&  
=2y8 CgLj  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦ÓᣠF8e<}v&7R  
$jd<v1"o  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£)  0Q593F  
M}DH5H"s  
ÃâÒßѧרҵ£º _,6f#t  
}.)s%4p8  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ u)Q;8$`  
f>$h@/-*  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? . BO<  
%;z((3F  
´«È¾²¡Ñ§×¨Òµ£º ?IX!+>.H  
r^HA aGpC  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ /T0nLp`gi  
>+cVs:  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ 'ul\Q `N3  
2 Tvvq(?T  
Ïû»¯×¨Òµ£º lS{r=y_0.  
<XQ.A3SG!  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ ++[5q+b  
% U`xu.  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? z&nZ<ih  
OQlG+|  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ Q^eJ4{Ya:  
FE5Q?*Ea  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© Uhh l3%p  
^9"KTZc-*  
1. Fas(CD95)/FasL >tRHNB_  
00vBpsZj2;  
2. common chain of cytokine receptor v:ER 4  
ce p$_J a  
3 . TCR/CD3 complex 2BB<mv K4  
yOHXY&  
4. negaive selection of thymocytes S0@T0y#  
~o15#Pfn/  
5. artificial active immune "HQF.#\#  
@ Gjny BJ  
6. anti-idiotypic A[/I#Im7  
hCc0sRp  
7. IgSF /NBTvTI  
4L:>4X[T  
8. Integrin E'dX)J9e$/  
FRyPeZR  
9. chemokine /8CY0Ey  
z:G}>fk5  
10. B7/CD28 H7IW"UkBR  
a1x7~)z>zi  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© `^8*<+  
[e4![G&y`  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ eK_*q -  
y lL8+7W  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ J|j;g!fK  
Ph)| j&]  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ Di.;<v#FL  
6Y?`=kAp  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ %8D?$v"#Z  
,YlQK;  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ WN0c %kz=  
$%He$t  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ @36S}5Oa  
/2w@ K_Px6  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© SfDQ;1?  
&z ksRX  
1. B7/CD28 hWxT!  
HDj$"pS  
2. Th1 subset ;Q90Y&{L=$  
dpn3 (  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© gb_X?j%p7  
UPO^V:.R4  
4. antibody affinity maturation 5B|,S1b  
u\5g3BH  
5. AP-1 %BICt @E  
Mdm0g  
6. single chain variable fragment£¨ScFv£© J0qXtr%h\  
%yhI;M^  
7. NK cell receptor Lupy:4AD  
AA.Ys89V  
8. Zinkernagel-Doherty phenomenon q\_DJ)qpn  
/&QQ p3  
9. Ig fold &%:*\_2s  
1gk0l'.z  
10. CD40/CD40L U%,;N\:_  
@ AggznA8  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© wzbz }P>  
@Q3, bj  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ >\&= [C  
F`3^wHw^  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ ~K%k 0kT  
]'6'<S  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ _ flg Q  
Eh {up  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ 9D%qXU  
5U3qr*/;m  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ _~:j3=1&n  
oFb\T iLu  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ .@Hmg  
prqT(1  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ 4p?+LdL  
sD2*x T  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© [#7D~Lx/  
{uEu >D$8  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© n}Vbdx lN  
>,kL p|gA  
1.Co-stimulators (or co-stimulating molecules) %7iUlO}}V  
'w'Dwqhmr  
2.NK-kB !~?W \b\:  
]"C| qR*  
3.Immunoglobulin superfamily D 7EXqo  
zoR,RBU6  
4.antigen-presenting cell (APC) G% o7BX  
9qnuR'BDu  
5.death domain +GRxH uW,  
qw6EPC  
6.CCR and CXCR Z@<q/2 ).|  
N-]\oMc2  
7.Lectin (or mitogen) Lr K9F^c  
"ugX /r$_  
8.Clusters of differentiation, CD) =%Q\*xaR.W  
t^`<*H  
9.B7 family qJ#L )  
sx<} tbG  
10.Cytotoxic T lymphocyte, CTL) tVC@6 Z$  
=~,$V<+c  
11.IL-15 and IL-15 receptor (IL-15R) ON:LPf>"-  
NvXj6U*%  
12.MHC restriction R tXF  
XMjI}SPG  
13.Affinity-chromatography s#'|{  
0L3Bo3:k  
14.Cyctosprin A, CsA '?&B5C  
dM);LT8@  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) sV9{4T~#|  
$#6 Fnhh}  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© 9$B)hrJo  
`XQx$I  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 J>,'P^  
yb@X*PW/z  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ h$#4ebp  
avYh\xZ  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ {Sd@u$&  
G #_(7X&  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© e#76h;  
hW*^1%1  
ÃâÒßѧרҵ£º XnNOj>!  
LbtlcpF*~5  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ I(iGs I  
&;uGIk>s  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ bi4^ zaCEE  
bUipp\[aV  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ 8yJk81 gY  
~@a) E+LsF  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) @n ~ND).  
N@%xLJF=N>  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) IArpCF/"8  
 K2vPj|  
1. ADCC(antibody dependent cell-mediated cytotoxicity) t&p:vXF2  
N8/Au= De_  
2. »·æß¾úËØ(cyclosporin) |?pYJkrYO  
W+-f `  
3. KIR(killer cell inhibitory receptor) /ab K/8ZQ  
&`\kb2uep  
4. HLDA(human leucocyte differentiation antigen) e-T9HM&%P  
r(/P||`l  
5. Interleukin 18(IL-18) pqNoL* H  
 # 8-P  
6. ÕûºÏËØ(integrin) 16d{IGMz  
u0$5Fd&X  
7. Fas/FasL a7 '\*  
8 )2u@sx%  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) 5 "Xo R)  
"} azC|:5  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) fjeE.  
jak|LOp  
10. Th1/Th2 X#\P.$  
>+W?!9[p:2  
11. »ùÒòÒßÃç(DNAÒßÃç) jl ?y}  
Zq6ebj  
12. chemokines and chemokine receptor L:];[xa%  
v(WL 3[y;  
13. ÃâÒßÄÍÊÜ +\]S<T*;  
!&<Wc ^PG  
14. ¹²´Ì¼¤·Ö×Ó i OA3x 8J  
boHm1hPKS  
15. ËÀÍö½á¹¹Óò(death domain) @zpHem dB  
)Z`viT  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) "Mu $3 w  
EC&1 9  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? X$Qi[=L  
iS^^Z ZyR  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦ÓᣠZi'8~iEH  
Tlv|To  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î E!]rh,mYK  
;@$," P  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ UM;bVf?  
AF nl t  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå Xwqf Wd_  
jYssz4)tp  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ N=}Z#  
oZ>]8vw  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) CX(yrP6;  
l<:)rg^,  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ Le+8s LE`Y  
MkIO0&0O  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ &S`'o%B  
sjbC~Te--  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
4+6=? ÕýÈ·´ð°¸:10
°´"Ctrl+Enter"Ö±½ÓÌá½»